Benjamin Landry Sells 6,175 Shares of Health Catalyst (NASDAQ:HCAT) Stock

Key Points

• Benjamin Landry, the General Counsel of Health Catalyst, sold 6,175 shares at an average price of $3.35, reducing his position by 4.17%.
• Analysts have recently downgraded Health Catalyst, with target prices now ranging between $3.00 and $5.00, leading to a consensus rating of "Hold" with an average target price of $4.73.
• Institutional investors hold a significant stake, owning 85% of Health Catalyst’s stock, demonstrating strong interest from hedge funds and asset management firms.

Health Catalyst, Inc. (NASDAQ:HCAT - Get Free Report) General Counsel Benjamin Landry sold 6,175 shares of Health Catalyst stock in a transaction that occurred on Friday, September 5th. The shares were sold at an average price of $3.35, for a total transaction of $20,686.25. Following the transaction, the general counsel directly owned 141,812 shares of the company's stock, valued at approximately $475,070.20. This trade represents a 4.17% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Health Catalyst Stock Performance

Shares of NASDAQ:HCAT traded down $0.11 during trading on Friday, hitting $3.13. 776,691 shares of the stock traded hands, compared to its average volume of 853,648. The company has a quick ratio of 1.83, a current ratio of 1.83 and a debt-to-equity ratio of 0.44. The company has a market cap of $220.27 million, a price-to-earnings ratio of -2.07 and a beta of 1.53. The company has a fifty day moving average price of $3.51 and a two-hundred day moving average price of $3.86. Health Catalyst, Inc. has a 52-week low of $2.52 and a 52-week high of $9.24.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on HCAT. Wells Fargo & Company decreased their target price on Health Catalyst from $10.00 to $6.00 and set an "overweight" rating on the stock in a research report on Monday, August 11th. Canaccord Genuity Group decreased their price objective on Health Catalyst from $9.00 to $5.00 and set a "buy" rating on the stock in a report on Friday, August 29th. Evercore ISI raised their price objective on Health Catalyst from $3.00 to $4.00 and gave the company an "in-line" rating in a report on Thursday, August 28th. Cantor Fitzgerald restated a "neutral" rating and issued a $4.00 price objective (down previously from $9.00) on shares of Health Catalyst in a report on Friday, August 8th. Finally, Stifel Nicolaus decreased their price objective on Health Catalyst from $5.50 to $4.50 and set a "hold" rating on the stock in a report on Friday, August 8th. Three analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus price target of $4.73.

Institutional Trading of Health Catalyst

A number of hedge funds and other institutional investors have recently modified their holdings of HCAT. Group One Trading LLC increased its position in shares of Health Catalyst by 107.6% during the 4th quarter. Group One Trading LLC now owns 4,360 shares of the company's stock worth $31,000 after purchasing an additional 2,260 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Health Catalyst by 7.9% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 36,047 shares of the company's stock worth $163,000 after purchasing an additional 2,624 shares during the last quarter. Campbell & CO Investment Adviser LLC increased its position in shares of Health Catalyst by 9.7% during the 2nd quarter. Campbell & CO Investment Adviser LLC now owns 43,051 shares of the company's stock worth $162,000 after purchasing an additional 3,808 shares during the last quarter. The Manufacturers Life Insurance Company increased its position in shares of Health Catalyst by 19.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 26,491 shares of the company's stock worth $100,000 after purchasing an additional 4,341 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD increased its position in shares of Health Catalyst by 8.3% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 62,443 shares of the company's stock worth $442,000 after purchasing an additional 4,798 shares during the last quarter. 85.00% of the stock is owned by institutional investors and hedge funds.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.